MX2024007765A - Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o. - Google Patents

Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o.

Info

Publication number
MX2024007765A
MX2024007765A MX2024007765A MX2024007765A MX2024007765A MX 2024007765 A MX2024007765 A MX 2024007765A MX 2024007765 A MX2024007765 A MX 2024007765A MX 2024007765 A MX2024007765 A MX 2024007765A MX 2024007765 A MX2024007765 A MX 2024007765A
Authority
MX
Mexico
Prior art keywords
treatment
combination
muscarinic receptor
task1
receptor antagonist
Prior art date
Application number
MX2024007765A
Other languages
English (en)
Inventor
Michael Hahn
Martina Delbeck
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2024007765A publication Critical patent/MX2024007765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación de bloqueantes selectivos de los canales TASK-1 y TASK-3, en particular derivados sustituidos de imidazo[1,2-a]pirimidina e imidazo[1,2-a]piridina de fórmula (I) y antagonistas del receptor muscarínico, para el tratamiento y/o profilaxis de trastornos respiratorios relacionados con el sueño, preferentemente apneas obstructivas y centrales del sueño y ronquidos.
MX2024007765A 2021-12-22 2022-12-20 Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o. MX2024007765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21216888 2021-12-22
PCT/EP2022/086933 WO2023118102A1 (en) 2021-12-22 2022-12-20 Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea

Publications (1)

Publication Number Publication Date
MX2024007765A true MX2024007765A (es) 2024-07-04

Family

ID=80123293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007765A MX2024007765A (es) 2021-12-22 2022-12-20 Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o.

Country Status (11)

Country Link
US (1) US20250057846A1 (es)
EP (1) EP4452246A1 (es)
JP (1) JP2024545696A (es)
KR (1) KR20240124998A (es)
CN (1) CN118434415A (es)
AU (1) AU2022418117A1 (es)
CA (1) CA3243049A1 (es)
IL (1) IL313652A (es)
MX (1) MX2024007765A (es)
TW (1) TW202342053A (es)
WO (1) WO2023118102A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097671A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
KR20180088462A (ko) 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) * 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
GEP20247606B (en) * 2018-11-27 2024-03-11 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CA3139298A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
WO2020225185A1 (en) 2019-05-09 2020-11-12 Bayer Aktiengesellschaft COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA
WO2021226020A1 (en) * 2020-05-05 2021-11-11 Apnimed, Inc. (Delaware) Polymorphic forms of (r)-oxybutynin hydrochloride
KR20230035349A (ko) * 2020-07-06 2023-03-13 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 알파2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 task1/3 채널 차단제의 조합물

Also Published As

Publication number Publication date
JP2024545696A (ja) 2024-12-10
CA3243049A1 (en) 2025-02-26
CN118434415A (zh) 2024-08-02
KR20240124998A (ko) 2024-08-19
US20250057846A1 (en) 2025-02-20
WO2023118102A1 (en) 2023-06-29
EP4452246A1 (en) 2024-10-30
AU2022418117A1 (en) 2024-07-11
IL313652A (en) 2024-08-01
TW202342053A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
PH12018501235A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
PH12019502828A1 (en) Diazabicylic substituted imidazopyrimides and their use for the treatment of breathing disorders
BRPI0811842A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero
NZ597122A (en) Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
WO2004041272A3 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
CY1111477T1 (el) Θειενοπυριδινες ως αλλοστερικοι ενισχυτες του μ4 μουσκαρινικου υποδοχεα
WO2005103039A8 (en) 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
MX2009007916A (es) Composiciones farmaceuticas que comprenden 3,5-diamino-6-(2,3-dicl orofenil)-l,2,4,-triazina; o r(-)-2,4-diamino-5-(2,3-diclorofenil) -6-fluorometil pirimidina y un receptor neuroquinina 1.
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
NZ592641A (en) 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment
CR10342A (es) INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3
MX2023000369A (es) Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño.
TW200730506A (en) Compounds and uses thereof
NO20080393L (no) Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater
MX2021003428A (es) Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño.
MX2024007765A (es) Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o.
MX2024007884A (es) Combinación de un bloqueador del canal task1/3 con un antagonista del receptor p2x3 para el tratamiento de la apnea del sueño.
MX2024007764A (es) Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
MX2007004976A (es) Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
IL206615A0 (en) Piperidine sulfonamide derivatives
MX2021006081A (es) Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios.
NZ603073A (en) Use of histamine h4 antagonist for the treatment of post-operative adhesions
WO2007076140A3 (en) Treatment methods employing histamine h3 receptor antagonists, including betahistine
MX2024007767A (es) Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o.